The markets opened mixed with the Dow slipping 10 points to 15,071 while Nasdaq rose 10 points to 3419.
On the upside
Molycorp (NYSE: MCP) widened first quarter losses but the results were better than expected.
Sequenom (Nasdaq: SQNM) widened losses for the first quarter but revenue more than doubled.
TheStreet upgraded Tesla Motors (Nasdaq: TSLA) to a Buy rating from Hold.
On the downside
Affymax (Nasdaq: AFFY) warned in its 10-Q filing that it may never achieve profitability and may not be able to continue operations if safety concerns over OMONTYS are not rectified by Takeda Pharmaceutical.
Pfizer (NYSE: PFE) has yet to decide whether it would continuing pursuing regulatory approval of Pain Therapeutics’ (Nasdaq: PTIE) abuse resistant pain treatment Remoxy. Remoxy was developed using Durect (Nasdaq: DRRX) technology.
Optimer Pharmaceuticals (Nasdaq: OPTR) widened first quarter losses more than expected.
In the broad market, advancing issues outpaced decliners by a margin of more than 9 to 7 on the NYSE and by more than 5 to 3 on Nasdaq. The broader S&P 500 index added 2 points to 1628.
